Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779243 | 0.90 | CA1 (0.69) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL16862971 | 0.87 | CA1 (0.58) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL14348204 | 0.83 | CA1 (0.73) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL5783666 | 0.81 | KDM4E (0.67) | CA1CA2CA9CA12ATM | |
| SCHEMBL5782961 | 0.81 | CA1 (0.70) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL31753307 | 0.80 | KMT2A (0.67) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL18688199 | 0.80 | CA9 (0.58) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL18669037 | 0.80 | CA9 (0.67) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL16863040 | 0.78 | CA1 (0.68) | CA1CA2CA9CA12TDP1 | |
| SCHEMBL9142818 | 0.77 | KDM4E (0.70) | CA1CA2CA9CA12TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408962-B1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-6933295-B2 | Substituted isoindoles and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-06 | — | — | US | disclosed |
| EP-1408962-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003007942-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | F2, SERPINC1, F11 | CA1 1242/4885CA2 732/4885CA9 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.